证券代码：300267 证券简称：尔康制药 公告编号：2023-027 湖南尔康制药股份有限公司 第五届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）第五届董事会第五次会议于 2023 年 8 月 25 日以现场会议和通讯表决相结合的方式召开。本次会议的通知于 2023 年 8 月 15 日以书面、邮件形式通知了全体董事。本次会议应参与表决的董 事 7 名，实际参与表决的董事 7 名，本次会议的通知、召开以及参与人数均符合 相关法律、法规、规则及《公司章程》的有关规定。 经全体董事认真审议，形成如下决议： 一、审议通过了《2023 年半年度报告》及其摘要 二、审议通过了《套期保值业务管理制度》 为规范公司及其子公司的套期保值业务，有效防范和控制风险，加强对套期 保值业务的管理，根据《中华人民共和国证券法》《上市公司信息披露管理办法》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《深圳证券交易所上市公司自律监管指引第 7 号——交易与关联交易》、期货交 易所有 ...

证券代码：300267 证券简称：尔康制药 公告编号：2023-025 二、整改说明 本次突发状况发生在凤凰实业下属中间体生产工厂，工厂 2022 年度资产总 额为 11,125.86 万元，占公司总资产比例为 1.90%。工厂发生突发状况，少量污 水流入马德望河，公司对此深感抱歉。 凤凰实业高度重视本次突发状况，立即成立应急处理小组，迅速采取针对性 措施，已对现有环保池进行堤坝加固、混凝土硬化，已完成澄清池开挖，并对现 有污水处理设施进行提质改造。同时，凤凰实业派出技术人员对沿河的水质进行 采样检测，检测结果均合格。公司后续将进一步增强环保意识，加强生产运营过 程中的控制与监督，严格执行环境保护制度的规定，切实履行环境保护职责。 湖南尔康制药股份有限公司 关于媒体报道相关情况说明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）于 2023 年 8 月 14 日关注 到媒体发布的"尔康制药柬埔寨工厂因违规倒废水 遭令搬迁和赔偿 50 万美元" 报道后，公司管理层高度重视，组织人员开展核查工作，现将相关情况公告 ...

湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------------|-------------------------------------------------------------| | | √特定对象调研 □ | 分析师会议 | | 投资者关系 | □媒体采访 □ | 业绩说明会 | | 活动类别 | □新闻发布会 □ | 路演活动 | | | □现场参观 | □其他（请文字说明其他活动内容） | | | 深圳市前海卓喜资产管理有限公司 | 曾子健 | | | 安信证券股份有限公司 | 崔巧玲 | | 参与单位名称及 | 江苏海创岛私募基金管理有限公司 | 李鑫媛 | | 人员姓名 | | 共青城宇嬴私募基金管理合伙企业（有限合伙）王式平 | | | 北京宏道投资管理有限公司 | 朱亚峰 | | | 星泓投资管理平阳有限公司 | 张明禹 | | 时间 | 2023 年 6 月 8 日 | 9:30-12:00 | | 地点 | 公司会议室 | | | | 董事、副 ...

3、公司是怎么考虑做碳酸锂的？感觉跨度有点大？ 回复：您好，感谢您的关注。经营业务转型升级一直是公司 发展规划的重点内容，公司在碳酸锂及其制剂项目建设、工艺流 程设计、人才储备等方面均有一定积累，并从产业政策、资金、 原材料资源、技术及团队情况以及市场情况等多维度深入开展了 可行性分析。本次涉足碳酸锂等锂化合物产品新领域，一方面可 以丰富公司产品品种，另一方面可以打造新的利润增长点，为公 司长期持续稳定发展增加后劲。 4、公司在去年的研发方面做了哪些工作? 证券代码：300267 证券简称：尔康制药 编号：2023-002 | | 特定对象调研 分析师会议 □ □ | | --- | --- | | 投资者关系活动 | □ 媒体采访 √ 业绩说明会 | | 类别 | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 (周五) 下午 2023 5 12 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w. ...

Financial Performance - The company's operating revenue for 2022 was ¥1,870,540,810.78, a decrease of 16.32% compared to ¥2,235,302,787.80 in 2021[18] - The net profit attributable to shareholders was ¥45,757,944.56, a significant turnaround from a loss of ¥791,202,027.47 in the previous year, representing a 105.78% increase[18] - The net cash flow from operating activities increased by 203.20% to ¥281,019,942.48, up from ¥92,683,406.31 in 2021[18] - Basic earnings per share improved to ¥0.0222 from a loss of ¥0.3836, marking a 105.79% increase[18] - Total assets at the end of 2022 were ¥5,855,659,382.96, reflecting a 7.80% increase from ¥5,431,979,242.78 in 2021[18] - The company's weighted average return on equity was 0.92%, a recovery from -14.83% in the previous year, indicating a 15.75% improvement[18] - Revenue from the pharmaceutical industry accounted for 95.39% of total revenue, amounting to ¥1,784,373,354.33, down 19.67% from the previous year[67] - The total cost for 2022 was CNY 1,454,904,548.74, a decrease of 15.09% compared to CNY 1,713,565,109.74 in 2021[71] - The gross profit margin for pharmaceutical excipients was 19.82%, a decrease of 3.90% from the previous year[67] Industry Overview - In 2022, the pharmaceutical industry in China saw a revenue of CNY 2,911.14 billion, a year-on-year decrease of 1.6%[28] - The total profit of the pharmaceutical industry in 2022 was CNY 428.87 billion, down 31.8% year-on-year[28] - The market for pharmaceutical excipients in China is expected to grow, with current production value only accounting for 3%-5% of the total pharmaceutical formulation value[29] Product and Business Segments - The company's main excipient products in 2022 included sucrose, pharmaceutical ethanol, pharmaceutical glycerin, citric acid series products, and composite excipients[41] - The company's raw material drug business includes the production of antibacterial and intermediate products, with key products being sulfanilamide, hydroquinone, and para-aminophenol[42] - The company’s finished drug business produced various injections and traditional Chinese medicines, including phenobarbital sodium injection and compound licorice tablets in 2022[43] - The auxiliary materials segment generated sales revenue of 1,168.56 million yuan, with specific products like sucrose series achieving 322.93 million yuan and compound auxiliary materials reaching 286.76 million yuan[50] - The raw materials segment reported sales revenue of 479.02 million yuan, with intermediate products contributing 342.64 million yuan and antibacterial raw materials generating 87.97 million yuan[51] - The finished pharmaceutical products segment had sales revenue of 136.79 million yuan, with injections accounting for 59.04 million yuan and traditional Chinese medicine products at 28.32 million yuan[51] Research and Development - The company is actively enhancing its research and development capabilities to meet the increasing demand for high-quality pharmaceutical excipients and to align with international standards[36] - Research and development expenses for 2022 were CNY 48,146,348.68, accounting for 2.57% of operating revenue, up from 2.19% in 2021[79] - The number of R&D personnel increased by 5.03% to 167, with the proportion of R&D staff rising to 11.16% of total employees[76] - The company is currently working on several new drug projects aimed at enhancing its product portfolio and competitive advantage[76] Corporate Governance - The company held 3 shareholder meetings during the reporting period, ensuring compliance with legal regulations and protecting minority shareholders' rights[118] - The board of directors consists of 7 members, including 3 independent directors, and operates under established rules to enhance decision-making[119] - The company maintains a complete and independent financial accounting system, ensuring no shared bank accounts with the controlling shareholder[123] - The company has established a transparent performance evaluation and incentive mechanism for senior management, adhering to legal standards[122] - The company emphasizes investor relations management, providing multiple communication channels to enhance engagement with minority investors[121] - The company has a clear governance structure, with the board, supervisory board, and management operating independently[123] Environmental Responsibility - The company reported a total environmental protection expenditure of 9.2451 million yuan in 2022, with 1.214 million yuan allocated to environmental engineering expenses[164] - The company has established a wastewater treatment facility with a daily capacity of 900 tons, which is currently operational and compliant with environmental standards[162] - The company has implemented a third-party monitoring scheme for environmental self-monitoring, ensuring compliance with discharge standards[164] - The company has developed emergency response plans for environmental incidents, with regular training and drills conducted[163] Employee Relations - The total number of employees at the end of the reporting period was 1,497, with 724 in production, 157 in technology, and 121 in sales[144][145] - The company aims to enhance employee skills and overall professional quality through a comprehensive training program in 2023[147] - The company has implemented a performance-based salary scheme linked to employee contributions and business development[146] Strategic Initiatives - The company plans to explore high-quality development paths and adjust its industrial structure to strengthen its leading position in the pharmaceutical excipients industry and gain a competitive edge in the new energy materials sector[100] - The company aims to consolidate its existing pharmaceutical business while expanding into the lithium compound industry, leveraging its extensive product range to enhance market competitiveness[101] - The company plans to deepen the value potential of pharmaceutical excipients by providing customized raw material solutions and improving service levels, focusing on modified starch and starch capsule products[102] Financial Management - The company has a total of ¥131,728,555.06 in restricted cash, including ¥13,128,550.14 in letter of credit deposits and ¥100,000,004.92 in bank acceptance bill deposits[90] - The company has not reported any significant changes in its financial performance metrics in the provided documents[126] - The company has maintained a stable management team, with key executives holding their positions until at least 2025[126] Legal and Compliance - The company has not reported any significant internal control deficiencies during the reporting period, indicating a stable control environment[155] - The company has not faced any bankruptcy reorganization issues during the reporting period[177] - The company has not reported any violations regarding external guarantees during the reporting period[173]

湖南尔康制药股份有限公司 2023 年第一季度报告 证券代码：300267 证券简称：尔康制药 公告编号：2023-013 湖南尔康制药股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第一季度报告是否经过审计 □是 否 湖南尔康制药股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减（%） | | 营业收入（元） | 546,925,468.79 | 426,347,681.19 | 28.28% | | 归属于上市公司股东 ...

证券代码：300267 证券简称：尔康制药 公告编号：2023-017 特此公告！ 湖南尔康制药股份有限公司（以下简称"公司"）已于2023年4月27日对外 披露《2022年年度报告》及其摘要，为了方便广大投资者更好、更深入地了解公 司经营情况，公司将于2023年5月12日（星期五）下午15:00-17:00举办2022年度 业绩网上说明会。本次年度业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（http://rs.p5w.net）参与本次年度业绩说明会。 出席本次年度报告说明会的人员有：公司董事长帅放文先生，董事会秘书顾 吉顺先生，董事、财务总监赵寻女士，独立董事代表谭雪先生。 为充分尊重投资者、提升交流的针对性，公司2022年度业绩说明会向投资者 公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年5月11日前访 问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。敬请广大投 资者通过全景网系统提交您所关注的问题，便于公司在业绩说明会上对投资者普 遍关注的问题进行回答，以便提升此次业绩说明会效率。此次活动交流期间，投 资者仍可登陆 ...

Group 1: Market Demand and Growth - The demand for hard capsules in China reached approximately 250 billion to 300 billion units by the end of 2013, with soft capsules at about 50,000 tons annually [2] - The capsule industry is expected to maintain an annual growth rate of around 15% during the "12th Five-Year Plan" period, resulting in an annual increase of approximately 20 billion capsules [2] Group 2: Research and Standards - The company has participated in the development of over 50 pharmaceutical excipient standards for the 2015 edition of the Pharmacopoeia of China, including various starches and other materials [3] - The public announcement period for the pharmaceutical excipient standards is three months [3] Group 3: Project Investment and Progress - The company invested 504.35 million yuan in the construction of a tapioca starch hollow capsule industrial park, with an expected annual production capacity of 30 billion capsules [3] - The project is progressing smoothly and is on track to meet production targets, barring any weather-related disruptions [3] Group 4: Financial Performance - In the first half of 2014, the revenue from pharmaceutical sucrose products increased by 127.64% compared to the same period last year, while the revenue from injectable sulbenicillin sodium products grew by 71.23% [3] Group 5: Market Feedback - Tapioca starch capsules are more widely accepted by consumers compared to gelatin capsules made from animal sources, appealing to groups such as Muslims, Hindus, and vegetarians [3] - There is growing interest from domestic and international clients regarding the company's starch capsule products [3]

Group 1: Company Position and Market Overview - The company is the world's first industrial producer of starch capsules and the only entity in China with a "National Engineering Research Center for Pharmaceutical Excipients" [2] - The company holds 39 national authorized patents and has stable partnerships with over 3,000 pharmaceutical companies across more than 30 provinces and cities in China [2][3] Group 2: Project Details - The non-public stock issuance project aims to produce 100 billion starch plant capsules and 30 billion starch plant soft capsules annually [2] - The total investment for the project is 2.5 billion RMB, with a construction period of 2 years [3] - Upon completion, the project is expected to generate an annual sales revenue of 3.84 billion RMB and a net profit of 1.3 billion RMB, indicating strong profitability and investment recovery potential [3] Group 3: Product Advantages - The starch plant capsules are made from 100% natural starch, ensuring safety and eliminating risks associated with animal-derived materials [3] - The capsules do not undergo cross-linking reactions, making them safe for use with common chemical drugs and traditional Chinese medicine [3] - The production process avoids any chemical additives, preservatives, or colorants, enhancing product safety [3] - The stability of the capsules is high due to their single-component structure, which is less prone to bacterial growth and spoilage [3] - The company has a subsidiary in Cambodia that produces 180,000 tons of cassava starch annually, ensuring a steady supply of raw materials for capsule production [3] Group 4: Marketing Strategy - The company employs a distributor-first sales model, leveraging existing sales networks of local distributors for rapid product promotion [4]